This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

According to a report by MarketWatch… Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring. complete report is on link below: Source: https://www.marketwatch.com/story/this-glp-1-drug-helped-people-maintain-their-weight-loss-in-a-clinical-trial-even-for-those-taking-it-once-a-month-f70929b5?mod=mw_rss_topstories